Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. In most people with Alzheimer’s, symptoms first appear in their mid-60s. Estimates vary, but experts suggest that more than 5 million Americans may have Alzheimer’s.
Alzheimer’s disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disorder may rank third, just behind heart
disease and cancer, as a cause of death for older people.
Scientists don’t yet fully understand what causes Alzheimer’s disease in most people. In people with early-onset Alzheimer’s, a genetic mutation is usually the cause. Late-onset Alzheimer’s arises from a complex series of brain changes that occur over decades. The causes probably include a combination of genetic, environmental, and lifestyle factors. The importance of any one of these factors in increasing or decreasing the risk of developing Alzheimer’s may differ from person to person.
Alzheimer’s disease is complex, and currently there is no cure. Current approaches focus on helping people maintain mental function,manage behavioral symptoms, and slow or delay the symptoms of disease, but with little long-term solutions.
North Springs is dedicated to finding a cure to this disease that affects the lives of so many people around the world. While several medications are approved by the U.S. Food and Drug Administration to treat symptoms of Alzheimer’s by regulating neurotransmitters, these drugs may help maintain thinking, memory, and communication skills, and help with certain behavioral problems, but don’t change the underlying disease process. Further, such drugs are effective for some but not all people and may help only for a limited time.
The cortex of the brain shrivels up damaging areas involved in thinking, planning, and remembering. Shrinkage is especially sever in the hippocampus, an area of the cortex that plays a key role in formation of new memories. Ventricles grow large furthering the damage done to the brain.
PoTen® - Potent ED Treatment With The Patented ED-Rx Applicator.
Erectile Dysfunction, Background & Market
First-line erectile dysfunction ("ED") treatment drugs include oral Viagra® (sildenafil), Cialis® (tadalafil), Levitra®(vardenafil) & Stendra® (avanafil). Primary care physicians, rather than urologists, are the predominant prescribers. Sexual stimulation is required for an erection with ED drugs. US sales of ED drugs exceeded $4.2 billion in 2012.
Oral ED drugs have systemic (side) effects. Only a small portion of the oral drug reaches the penis. ED drugs promote blood flow into the corpora cavernosa to the point that inreased pressure cuts off out flow and causes an erection. The ED drugs eventually break down and the blood flows out allowing the erection to subside.
Oral ED Drug Failures, Causes and Incidence
A study published in 2007 (New England Journal of Medicine) reported 18.4% of men over age 20 and 40% over age 64 having difficulty with ED. In men who cannot use or are unable to achieve/keep an erection with oral ED drugs (approximately 6 million in US alone), the medication is either not present in sufficient quantity, has intolerable side effects (including headache, dizziness, flushing, eye redness, nausea, visual disturbances, nose bleeds and low blood pressure ) or, cannot be taken safely with other drugs (e.g., nitrates, certain blood pressure medications, antibiotics, etc.).
What next if Viagra® doesn't work? Overall, for every one satisfied customer there is one oral drug "failure" (50%). For those with more severe ED due to aging, diabetes, prostate surgery, nerve-spinal cord injury & certain medication users, the failure rate becomes substantially greater than 50%.
PoTen® For ED Oral Drug Failures
Media attention (ads) for oral ED drugs, increased longevity, stigma of impotence, have all contributed to higher sexual expectations-demand for effective treatment-in aging males.
Intracavernosal application treatment is the most effective (non-surgical) therapy for all causes of ED, including oral drug failures. PoTen® can administer a variety of combinations of highly effective drugs from a patented autoinjector that work directly in the area of application.
Medication mixtures administered by PoTen® (e.g., papaverine/alprostadil; vasoactive intestinal polypeptide/phentolamine, etc.) eliminate any systemic side effects and cause an erection within 1-10 minutes that will last for approximately 30-90 minutes. Further, depending on the final chosen combination of drugs, erections can occur even without need for sexual stimulation. Finally, PoTen® eliminates all visual treatment (needle) phobia and can be used discretely, without knowledge of the sexual partner.
Forward Looking Statement:
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This website includes various"forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company’s expectations or beliefs concerning future events. Statements containing expressions such as “believes,”“anticipates,” “intends,” or “expects,” used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
This website and its content is copyright of North Springs Pharmaceutical Group - © North Springs Pharmaceutical Group. 2016. All rights reserved.